Kura Oncology (NASDAQ:KURA) COO Kathleen Ford Sells 1,813 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 1,813 shares of the stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $15,337.98. Following the sale, the chief operating officer owned 153,560 shares of the company’s stock, valued at $1,299,117.60. This trade represents a 1.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Kathleen Ford also recently made the following trade(s):

• On Friday, November 14th, Kathleen Ford sold 6,902 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total value of $77,164.36.

Kura Oncology Trading Down 1.2%

Shares of NASDAQ KURA opened at $8.47 on Wednesday. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $12.49. The company has a market cap of $737.06 million, a price-to-earnings ratio of -3.42 and a beta of 0.25. The business has a fifty day simple moving average of $10.33 and a 200-day simple moving average of $9.05.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. Sell-side analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analyst Ratings Changes

KURA has been the topic of several research analyst reports. JMP Securities reiterated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. UBS Group upped their price target on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Zacks Research downgraded Kura Oncology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 20th. Finally, Barclays reaffirmed an “overweight” rating and set a $28.00 target price (up previously from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

• Negative Sentiment: Teresa Brophy Bair (insider) sold 11,208 shares at an average price of $8.46 for proceeds of $94,819.68; her post-sale holdings are 226,931 shares (down ~4.71%). Read More.
• Negative Sentiment: Francis Burrows (insider) sold 1,311 shares at $8.46 for proceeds of $11,091.06; post-sale holdings 32,424 shares (down ~3.89%). Read More.
• Negative Sentiment: Thomas James Doyle (SVP) sold 7,142 shares at $8.46 for proceeds of $60,421.32; post-sale holdings 145,167 shares (down ~4.69%). Read More.
• Negative Sentiment: Mollie Leoni (insider) sold 8,180 shares at $8.46 for proceeds of $69,202.80; post-sale holdings 267,274 shares (down ~2.97%). Read More.
• Negative Sentiment: Kathleen Ford (COO) sold 1,813 shares at $8.46 for proceeds of $15,337.98; post-sale holdings 153,560 shares (down ~1.17%). Read More.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Kura Oncology by 41.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,363 shares of the company’s stock worth $482,000 after purchasing an additional 13,579 shares in the last quarter. Merit Financial Group LLC raised its position in Kura Oncology by 124.0% during the fourth quarter. Merit Financial Group LLC now owns 22,499 shares of the company’s stock valued at $234,000 after acquiring an additional 12,454 shares in the last quarter. Xcel Wealth Management LLC lifted its stake in Kura Oncology by 16.2% in the fourth quarter. Xcel Wealth Management LLC now owns 118,846 shares of the company’s stock valued at $1,235,000 after acquiring an additional 16,525 shares during the last quarter. CWM LLC grew its position in Kura Oncology by 32.3% in the fourth quarter. CWM LLC now owns 156,544 shares of the company’s stock worth $1,626,000 after acquiring an additional 38,181 shares in the last quarter. Finally, Flower City Capital increased its stake in shares of Kura Oncology by 20.0% during the 4th quarter. Flower City Capital now owns 12,000 shares of the company’s stock worth $125,000 after purchasing an additional 2,000 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.